ライフサイエンスコーパス: pituitary adenoma

1 r 1, typically resulting from a GH-secreting pituitary adenoma.

2 owth hormone, most commonly arising due to a pituitary adenoma.

3 and influence the prognosis and treatment of pituitary adenoma.

4 ely among different histological subtypes of pituitary adenoma.

5 nsus guideline to cover the care of CYP with pituitary adenoma.

6 el mutation of DKC1 (DKC1(S485G)) in a human pituitary adenoma.

7 like growth factor I (IGF1), most often by a pituitary adenoma.

8 repared from a human pituitary nonfunctional pituitary adenoma.

9 eningioma tumors was higher than uptake into pituitary adenoma.

10 on 4 patients after surgical removal of the pituitary adenoma.

11 in the development of a subgroup of sporadic pituitary adenomas.

12 s and TGF-beta-RII in normal pituitaries and pituitary adenomas.

13 s on recent developments in the treatment of pituitary adenomas.

14 ective in the treatment of hormone-secreting pituitary adenomas.

15 eningiomas, 10 vestibular schwannomas and 31 pituitary adenomas.

16 her conditions such as aseptic meningitis or pituitary adenomas.

17 , therapy and outcomes for all patients with pituitary adenomas.

18 emerged as promising new approaches to treat pituitary adenomas.

19 lomo et al. performed a whole-exome study of pituitary adenomas.

20 ormone secreting and nonsecreting (NS) human pituitary adenomas.

21 endoscopic than with microscopic removal of pituitary adenomas.

22 increasingly more popular for the removal of pituitary adenomas.

23 rgeted treatment for corticotropin-secreting pituitary adenomas.

24 or growth in a mouse model of ACTH-secreting pituitary adenomas.

25 an update on the diagnosis and treatment of pituitary adenomas.

26 portant for the progression of nonfunctional pituitary adenomas.

27 annoma, testicular Sertoli-cell tumours, and pituitary adenomas.

28 ction in treating patients with GH-secreting pituitary adenomas.

29 al genes with altered expression patterns in pituitary adenomas.

30 and identified as being under-represented in pituitary adenomas.

31 fashion with pttg in experimental and human pituitary adenomas.

32 nd bFGF expression in experimental and human pituitary adenomas.

33 ses on developments in treatment options for pituitary adenomas.

34 h was used as a positive control, but not in pituitary adenomas.

35 yperplasia, pancreatic endocrine tumors, and pituitary adenomas.

36 e diagnoses were 19 meningiomas (0.52%), six pituitary adenomas (0.16%), five cavernous malformations

37 1), glioblastoma (1.14, 1.01-1.28, p=0.038), pituitary adenoma (1.13, 1.05-1.22, p<0.0001), and vesti

38 ), glioblastoma (1.19, 1.12-1.28, p<0.0001), pituitary adenoma (1.21, 1.16-1.25, p<0.0001), and vesti

39 ecommendation against surgical resection for pituitary adenoma (1.80, 1.41-2.30, p<0.0001) and vestib

40 oma (meningioma [1.18, 1.08-1.28, p<0.0001], pituitary adenoma [1.20, 1.09-1.31, p<0.0001], and vesti

41 irm this initial report that the majority of pituitary adenomas (22 of 33; 67%) do not express GADD45

42 4 genes from the DLK1-MEG3 locus in 44 human pituitary adenomas (25 NFAs, 7 ACTH-secreting, 7 GH-secr

43 cted in four oligodendrogliomas (17.4%), one pituitary adenoma (3.2%), one meningioma (2.4%), one ast

44 22.2%]), trigeminal neuralgia (565 [11.5%]), pituitary adenomas (641 [13.1%]), haemangioblastoma (29

45 Clinically manifest pituitary adenomas affect approximately 1 in 1100 people

46 A specific MEN1 mutation was detected in a pituitary adenoma and corresponding germ-line DNA in a p

47 ecretion is usually caused by a GH-secreting pituitary adenoma and leads to acromegaly - a disorder o

48 The most common etiologies were pituitary adenoma and meningioma.

49 nfirmed in a validation group of 37 surgical pituitary adenomas and 11 normal pituitary glands.

50 87.5%) ACTH carcinomas, but not in 112 other pituitary adenomas and carcinomas.

51 rgical resection is indicated for incidental pituitary adenomas and cystic sellar lesions.

52 ular basis, we investigated 11 nonfunctional pituitary adenomas and eight normal pituitary glands, us

53 xcessive hormonal production from functional pituitary adenomas and generally classify pituitary aden

54 multiple, clinically relevant parameters on pituitary adenomas and may represent a valuable therapeu

55 Pituitary adenomas and NETs exhibit some morphological a

56 l distribution of pancreastatin secretion in pituitary adenomas and that the hypothalamic hormone gon

57 ndocrine cancers including pheochromocytoma, pituitary adenoma, and small cell lung cancer.

58 edial wall resection was performed in 47% of pituitary adenomas, and 39/50 walls confirmed pathologic

59 ), and p27 expression in normal pituitaries, pituitary adenomas, and carcinomas to analyze the possib

60 atively constant in nontumorous pituitaries, pituitary adenomas, and carcinomas, indicating that p27

61 the gene product in nontumorous pituitaries, pituitary adenomas, and carcinomas.

62 benign schwannomas, WHO grade 1 meningiomas, pituitary adenomas, and haemangioblastoma.

63 Normal pituitary, pituitary adenomas, and pituitary carcinomas all express

64 nd molecular classification of nonfunctional pituitary adenomas, and suggest that therapeutic targeti

65 , but not in normal anterior pituitary or in pituitary adenomas, and the differential expression of P

66 Pituitary adenomas are classified as either macroadenoma

67 Pituitary adenomas are frequently encountered in practic

68 However, unlike NETs, pituitary adenomas are highly prevalent, yet indolent an

69 As commonly encountered, pituitary adenomas are invariably benign.

70 Although pituitary adenomas are monoclonal proliferations, somati

71 Pituitary adenomas are neoplasms of the pituitary adenoh

72 Thirty percent of pituitary adenomas are nonfunctioning adenomas, which do

73 Approximately 53% of pituitary adenomas are prolactinomas, which can cause hy

74 Pituitary adenomas are rare in children and young people

75 mours and of Central Nervous System Tumours, pituitary adenomas are reclassified as neuroendocrine tu

76 eric for Rb deficiency, invariably died from pituitary adenomas by 3 months.

77 d in normal pituitaries and in all groups of pituitary adenomas by RT-PCR, whereas PVR-1 and -3 mRNAs

78 al pituitary adenomas and generally classify pituitary adenomas by using statistical and machine lear

79 Pituitary adenomas can develop sporadically or as a part

80 Pituitary adenomas cause significant morbidity caused by

81 GF-beta1-induced apoptosis in the HP75 human pituitary adenoma cell line and that PACAP, TGF-beta1, f

82 Analysis of the cultured human pituitary adenoma cell line HP75, which expresses all th

83 An immortalized human pituitary adenoma cell line, HP75, developed in our labo

84 ted cell cycle protein p27 in the HP75 human pituitary adenoma cell line.

85 GH transcription and secretion in senescent pituitary adenoma cells and also in nonpituitary (human

86 AR-gamma is an important molecular target in pituitary adenoma cells and PPAR-gamma ligands inhibit t

87 Interestingly, in cultured pituitary adenoma cells In1-ghrelin treatment (acylated

88 Pituitary adenomas cells cultured for 7 days in defined

89 Pituitary adenomas comprise 10% of intracranial tumors a

90 Pituitary adenomas comprise a heterogeneous subset of pa

91 ogues in primary human GH- and PRL-secreting pituitary adenoma cultures.

92 s to accelerate medullary thyroid C cell and pituitary adenoma development.

93 and, a large anterior mediastinal mass and a pituitary adenoma during a study done to evaluate recurr

94 ounts of immunoreactive pancreastatin in all pituitary adenomas except prolactin adenomas.

95 and -3 mRNAs were expressed in all groups of pituitary adenomas, except for most prolactinomas.

96 ypes I and II binding sites in all groups of pituitary adenomas, except prolactinomas.

97 Pituitary adenomas expressing and secreting GH are invar

98 targeted therapy of clinically nonfunctional pituitary adenomas, for which there is currently no medi

99 Functional pituitary adenomas (FPAs) are associated with hormonal h

100 ic pituitary adenomas from 38 patients and 1 pituitary adenoma from a familial MEN1 patient were exam

101 secutive patients who underwent 219 EETS for pituitary adenoma from February 2007 and July 2018.

102 3-mediated senescence, likely protecting the pituitary adenoma from progression to malignancy.

103 gene in pituitary tumorigenesis, 39 sporadic pituitary adenomas from 38 patients and 1 pituitary aden

104 is receptor in normal anterior pituitary and pituitary adenomas, GHRH-R mRNA was analyzed in 2 normal

105 r methods in the diagnosis and treatment for pituitary adenomas greatly expand our ability to care fo

106 Drivers of sporadic benign pituitary adenoma growth are largely unknown.

107 le of PACAP in regulating apoptosis in human pituitary adenomas has not previously been examined.

108 status of other genes at this locus in human pituitary adenomas has not previously been reported.

109 primary lesions included craniopharyngioma, pituitary adenoma, Hodgkin's lymphoma, ependymoma, pinea

110 sampling correctly identified ACTH-secreting pituitary adenomas in 80% of patients with proven Cushin

111 Given the link between Hh signaling and pituitary adenomas in humans, our data suggest misregula

112 We describe cells isolated from pituitary adenomas in two patients with multiple endocri

113 iterature reveals that endoscopic removal of pituitary adenoma, in the short term, does not seem to c

114 report describes the analysis of inheritable pituitary adenomas induced by expression of the human po

115 For all other pituitary adenomas, initial therapy is generally transsp

116 that transsphenoidal microscopic removal of pituitary adenomas is a well-established procedure with

117 ACTH-secreting pituitary adenomas lead to hypercortisolemia and cause s

118 used by adrenocorticotropin (ACTH)-secreting pituitary adenomas leads to hypercortisolemia predisposi

119 Pituitary adenomas may hypersecrete hormones or cause ma

120 uble null mice, on the other hand, developed pituitary adenomas, multifocal gastric neuroendocrine hy

121 22 673), glioblastoma (n=35 258; n=104 047), pituitary adenoma (n=27 506; n=87 772), vestibular schwa

122 in, in human normal pituitaries (n = 11) and pituitary adenomas (n = 169) revealed that expression pa

123 /secretion, cell viability and apoptosis) in pituitary adenomas (n = 74), and to compare with the res

124 Non-functioning pituitary adenomas (NFPAs) are the most frequent pituita

125 Clinically evident pituitary adenomas occur in approximately 1 in 1100 pers

126 ange, 29-82 y) with clinically nonfunctional pituitary adenomas on MRI underwent preoperative imaging

127 study, we evaluated 107 consecutive primary pituitary adenomas operated on by a single neurosurgeon

128 Pituitary histopathology did not uncover any pituitary adenomas or somatotroph hyperplasia in either

129 and the most common cause in adulthood is a pituitary adenoma, or treatment with pituitary surgery o

130 Pituitary adenoma (PA) is one of the most common intracr

131 However, the potential role of LDHA in pituitary adenoma (PA) remains unknown.

132 ne tissues, including parathyroid neoplasia, pituitary adenomas, pancreatic neuroendocrine tumors, an

133 Pituitary adenomas (PAs) are benign growths arising from

134 To date, no studies are available in which pituitary adenomas (PAs) have been studied using techniq

135 The complete resection of pituitary adenomas (PAs) is unlikely when there is an ex

136 In most patients with suspected or confirmed pituitary adenomas (PAs), MRI, performed using T1- (with

137 Tissue analysis confirmed a pituitary adenoma/pituitary neuroendocrine tumor of the

138 Observations: Prevalence of pituitary adenomas ranges from 1 in 865 adults to 1 in 2

139 CYP with suspected pituitary adenomas require careful clinical examination,

140 tary surgery is first-line therapy for other pituitary adenomas requiring treatment.

141 ebrospinal fluid (CSF) leaks during EETS for pituitary adenoma resection.

142 neal shunts for presumed IIH and had a prior pituitary adenoma resection.

143 endonasal transsphenoidal surgery (EETS) for pituitary adenoma resection: TachoSil patching versus Du

144 te that overexpression of FRalpha mRNA by NF pituitary adenomas results in production of properly fol

145 In humans, excess GH secretion due to pituitary adenoma, seen in patients with acromegaly, res

146 Patients with pituitary adenomas should be identified at an early stag

147 Four of 39 sporadic pituitary adenomas showed a deletion of one copy of the

148 ome sequencing of 159 prospectively resected pituitary adenomas showed that somatic copy number alter

149 f-function AIP mutations are associated with pituitary adenomas, suggesting that AIP acts as a tumor

150 t-term results of endoscopic and microscopic pituitary adenoma surgery.

151 erred to as CYP) presenting with a suspected pituitary adenoma to inform specialist care and improve

152 implications of the classification change of pituitary adenoma to NET.

153 markers to predict the ultimate response of pituitary adenomas to BIM-23A760.

154 disposition for a wide range of tumors, from pituitary adenomas to pancreatic and liver cancers, comm

155 ould contribute to pathogenesis of different pituitary adenomas types, and suggest that this variant

156 2 normal human pituitary glands and 16 human pituitary adenomas using in situ hybridization.

157 o assay of folate receptors in nonfunctional pituitary adenomas using preoperative (99m)Tc-folate SPE

158 tracer may have promise for the detection of pituitary adenomas, using PET.

159 a new diagnosis of meningioma, glioblastoma, pituitary adenoma, vestibular schwannoma, astrocytoma, a

160 S and pseudo-MS/MS methods, and subtyping of pituitary adenomas was performed by using principal comp

161 Compared with adult patients with pituitary adenomas, we highlight that, in the CYP group,

162 ry roles of PACAP and its receptors in human pituitary adenomas, we investigated the expression of va

163 atin on pituitary cell function, 17 cultured pituitary adenomas were examined for immunoreactive panc

164 uence and mRNA levels appear normal in human pituitary adenomas while p27 protein levels are decrease

165 we find that Max inactivation alone produces pituitary adenomas, while Max inactivation cooperates wi

166 te adequate neurosurgical decompression of a pituitary adenoma with compression of the optic apparatu

167 tuitary tumors, and in 23 of 26 GH-producing pituitary adenomas with high PTTG levels, senescence was